semaglutide mash fda approval Exciting Phase 3 Data from Novo Nordisk for Patients with GI and Hepatology News Novo's Wegovy becomes first GLP-1

doi:10.1371/journal.pone.0069010 162

Safety and Side Effects Common Side Effects Injection site discomfort Nausea Mild allergic reactions Serious Risks Severe allergic reactions (rare) Improper administration complications Medical supervision is essential during therapy

I believe we need a clinical trial to determine if semaglutide significantly reduces the risk of arthrofibrosis returning after surgery, beginning treatment before surgery and continuing for three months post-op

Changes in the levels and composition of BAs modulate the composition of the gut microbiota

Originally for diabetes and weight loss, new studies have shown they could protect brain cells and preserve memory